Short answer
Xencor Inc (XNCR) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $5M (down 86.2% year over year) with net income of −$129M.
Q1 2026 key financials · XBRL
- Revenue
- $5M
- −86.2% YoY
- Net income
- −$129M
- −166.3% YoY
- Operating margin
- -1724.1%
- EPS (diluted)
- −$1.71
- −159.1% YoY
Source: XBRL data from the Xencor Inc (XNCR) Q1 2026 10-Q on SEC EDGAR. USD.
Xencor Inc Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Clinical-stage portfolio spanning early- and mid-stage programs, with three marketed medicines using XmAb technologies
- Portfolio management focused on advancing, partnering, or discontinuing programs based on clinical data and priorities
Risk Factors
- Director trading arrangement covering 5,064 shares through June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xencor Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.